Cardiovascular disease researchers reported a striking result this year: a single intravenous infusion of an investigational gene‑editing medicine, VERVE‑102, produced large, dose‑dependent and durable reductions in the protein PCSK9 and in low‑density lipoprotein cholesterol (LDL‑C), the lipid most closely linked to atherosclerotic heart disease. The Phase 1b Heart‑2 study gave one dose of VERVE‑102 to adults with heterozygous familial hypercholesterolemia or premature coronary artery disease and followed them for months. The results were published in the New England Journal of Medicine and presented at a major cardiology meeting. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2601283?af=R&rss=currentIssue&utm_source=openai))
What the treatment does
VERVE‑102 uses an approach called adenine base editing delivered to the liver inside a lipid nanoparticle. Rather than cutting DNA like traditional CRISPR‑Cas9, base editors chemically convert a single DNA letter at a targeted site — here, the PCSK9 gene — to permanently inactivate that gene in hepatocytes. Because people who naturally carry loss‑of‑function PCSK9 variants have much lower lifetime risk of coronary events, researchers have long seen PCSK9 as an attractive target for durable intervention. ([nature.com](https://www.nature.com/articles/s41587-023-02070-6?utm_source=openai))
How much effect was seen
In the study, reductions in circulating PCSK9 protein and LDL‑C were dose dependent: the highest evaluated dose produced a mean PCSK9 fall of as much as 88% and a corresponding mean LDL‑C reduction of as much as 62% compared with baseline, with some participants showing durable responses across many months of follow‑up. Those numbers come from the trial report in NEJM and the sponsor’s release. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2601283?af=R&rss=currentIssue&utm_source=openai))
Why this matters
If the effect and safety profile seen so far hold up in larger trials and longer follow‑up, a one‑time treatment that mimics protective human PCSK9 variants could transform care for people who require deep LDL lowering. Today many patients need lifelong pills and periodic injections to manage high LDL; a durable one‑and‑done option would be a fundamentally different model. Investigators and the company say the early data support moving into larger studies. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88?utm_source=openai))
Safety and limits — why caution remains
These are early phase results from a small open‑label study. The trial report notes that no dose‑limiting toxic effects were observed, but participants did experience infusion‑related reactions and some transient liver enzyme elevations; one participant had aspiration pneumonitis that was recorded among adverse events. The researchers emphasize the need for longer follow‑up and larger, randomized trials to characterize uncommon risks, measure long‑term durability, and confirm clinical benefits such as fewer heart attacks and strokes. Because base editing permanently changes DNA in liver cells, regulators and investigators require extended safety monitoring for off‑target editing, immune responses, or late consequences. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2601283?af=R&rss=currentIssue&utm_source=openai))
How the trial fits into a fast‑moving field
VERVE‑102 builds on earlier work showing that in‑body base editing can lower cholesterol: prior first‑in‑human experiments with related base‑editing approaches gave investigators confidence to test more advanced candidates and dosing. Academic groups and companies are now testing several different one‑shot editing strategies aimed at lipid genes (PCSK9, ANGPTL3 and others), driven by the clear genetic evidence linking these targets to lifelong heart‑disease risk. The new VERVE‑102 report is notable because of the size of the lipid drops and the degree of durability reported so far. ([nature.com](https://www.nature.com/articles/s41587-023-02070-6?utm_source=openai))
What comes next
The sponsor and investigators have said they will expand testing to larger, controlled trials that measure both safety and whether durable LDL lowering translates into fewer cardiovascular events. The VERVE‑102 program is registered with clinical trial identifiers and continues to recruit in expanded sites while regulators and independent safety monitors oversee follow‑up. Any future approvals would depend on robust evidence of both safety and clinical benefit. ([scge.mcw.edu](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06164730?utm_source=openai))
Bottom line
The VERVE‑102 findings are an encouraging demonstration that a single in‑body base‑editing infusion can substantially and durably lower circulating PCSK9 and LDL‑C in people at high cardiovascular risk. The results do not yet prove that the treatment will prevent heart attacks or be broadly safe and effective, but they mark a clear milestone: gene editing delivered directly to patients can produce meaningful, sustained changes in a major risk factor for disease.
